← Leaderboards
Kurt L. Krause
University Of Houston
$2,514,914
Attributed
$2,514,914
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,514,914 · 2
By mechanism
R01$1,997,557 · 1
R21$517,357 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Enzyme Inhibitors”
- Randall J Bateman · Washington University$62,893,538
- David Heimbrook · Leidos Biomedical Research, Inc.$43,975,020
- Vern L. Schramm · Yeshiva University$28,993,424
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$25,909,597
- Richard M Weinshilboum · Mayo Clinic Coll Of Medicine, Rochester$25,509,522
- Benjamin F Cravatt · Scripps Research Institute$25,494,660
Research focus
Enzyme InhibitorsDrug Design /Synthesis /ProductionAidsAntibioticsEnzyme StructureEscherichia ColiIsomeraseMicroorganism Disease ChemotherapyMycobacterium AviumMycobacterium TuberculosisOpportunistic InfectionsPolymerase Chain ReactionStreptococcus PneumoniaeX Ray CrystallographyMolecular CloningYellow Fever VirusTissue /Cell CultureCrystallizationChemical SynthesisBiotherapeutic AgentVirus ProteinEpidemic EncephalitisWest Nile VirusFlaviviridae
Grant awards (6)
Targets for Drug Design In Flaviviral Infection$252,616
R21 · FY2004 · AI
DRUG DESIGN FOR TREATING OPPORTUNISTIC INFECTION IN AIDS$538,055
R01 · FY2003 · AI
Targets for Drug Design In Flaviviral Infection$264,741
R21 · FY2003 · AI
DRUG DESIGN FOR TREATING OPPORTUNISTIC INFECTION IN AIDS$448,061
R01 · FY2002 · AI
DRUG DESIGN FOR TREATING OPPORTUNISTIC INFECTION IN AIDS$507,169
R01 · FY2001 · AI
DRUG DESIGN FOR TREATING OPPORTUNISTIC INFECTION IN AIDS$504,272
R01 · FY2000 · AI